- My News
- All News
- Most Popular
RNS System Clinical Trials included 256 adult patients from the feasibility trial, pivotal trial, and long-term treatment trial, representing 1,825 implant years and average follow up of 8.1 years. Key findings from these prospective trials demonstrate sustained, long-term patient benefits including:
"In addition to compelling therapeutic benefits, the RNS System is the only device that provides information about a patient's brain activity over months and years," notes Martha Morrell, MD, Chief Medical Officer at NeuroPace. "With over 1.5 million stored brain recordings, the unprecedented data from the RNS System is helping us advance science. It is fueling research on seizure biomarkers, seizure forecasting, effects on memory, and possible synergies between specific antiepileptic medication and neuromodulation. We are optimistic that the clinical insights gained from this large body of data will continue to help clinicians improve their patients' outcomes."
For a full list of posters, visit www.neuropace.com/aes-2017. Selected poster highlights include:
About the NeuroPace RNS® System
The RNS System is the world's first and only closed-loop brain-responsive neurostimulation system designed to prevent epileptic seizures at their source. The RNS System treats seizures by continuously monitoring brain waves, detecting unusual activity, and automatically responding with imperceptible electrical pulses before seizures occur. Physicians can program the detection and stimulation parameters of the implanted RNS neurostimulator to personalize therapy for each individual. The RNS® System is an adjunctive therapy for adults with refractory, partial onset seizures with no more than 2 epileptogenic foci.
NeuroPace is an innovative medical device company dedicated to improving quality of life for individuals with medically refractory partial onset seizures. In addition to treating epilepsy, responsive neurostimulation holds the promise of treating other disabling neurological, psychiatric, and chronic disorders that negatively impact quality of life for millions of patients throughout the world.
Source: NeuroPace, Inc.
Did you like this article?